EyePoint cuts workforce by 53% after Phase 3 readout in wet AMD fails
EyePoint announced a strategic reduction of its workforce by over half and a pause of wet AMD trials following a failed Phase 3 study for DURAVYU, shifting focus to its DME program to conserve $30 million in annual cash.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed